Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
72
HLN Quote, Financials, Valuation and Earnings
Last price:
$9.72
Seasonality move
:
2.79%
Day range:
$9.63 - $9.75
52-week range:
$7.89 - $10.80
Dividend yield:
1.62%
P/E ratio:
28.73x
P/S ratio:
3.13x
P/B ratio:
2.09x
Volume:
5.5M
Avg. volume:
7.2M
1-year change:
19.26%
Market cap:
$43.9B
Revenue:
$14.1B
EPS (TTM):
$0.34
Analysts' Opinion
-
Consensus RatingHaleon PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Haleon PLC has an estimated upside of 10.65% from its current price of $9.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $9.72.
Fair Value
-
According to the consensus of 0 analysts, Haleon PLC has 10.65% upside to fair value with a price target of -- per share.
HLN vs. S&P 500
-
Over the past 5 trading days, Haleon PLC has underperformed the S&P 500 by -1.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Haleon PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Haleon PLC has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Haleon PLC reported revenues of $3.6B.
Earnings Growth
-
Haleon PLC has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Haleon PLC reported earnings per share of $0.14.
Enterprise value:
54.5B
EV / Invested capital:
--
Price / LTM sales:
3.13x
EV / EBIT:
19.24x
EV / Revenue:
3.82x
PEG ratio (5yr expected):
17.14x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
19.24x
Gross Profit (TTM):
$8.6B
Return On Assets:
3.21%
Net Income Margin (TTM):
10.85%
Return On Equity:
5.94%
Return On Invested Capital:
4.19%
Operating Margin:
25.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $12.1B | $15.1B | $14.3B | $3.5B | $3.6B | |
| Gross Profit | $7.6B | $9.1B | $8.6B | $2.2B | $2.3B | |
| Operating Income | $2.1B | $2.8B | $2.7B | $739.5M | $917.4M | |
| EBITDA | $2.1B | $2.9B | $2.8B | $739.5M | $931.7M | |
| Diluted EPS | $0.39 | $0.33 | $0.34 | $0.10 | $0.14 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.4B | -- | -- | $937.5M | $1.1B | |
| Cash From Investing | -- | -- | -- | -$235.3M | $296.5M | |
| Cash From Financing | -- | -- | -- | -$848.6M | -$2B | |
| Free Cash Flow | -- | -- | -- | $757.3M | $921M | |
HLN
Sector
Market Cap
$43.9B
$347.3M
Price % of 52-Week High
90%
73.63%
Dividend Yield
1.62%
0%
Shareholder Yield
--
2.64%
1-Year Price Total Return
19.26%
-13.33%
Beta (5-Year)
--
0.504
Dividend yield:
1.62%
Annualized payout:
$0.00
Payout ratio:
31.66%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.74
200-day SMA
Buy
Level
$9.21
Bollinger Bands (100)
Sell
Level
9.57 - 10.31
Chaikin Money Flow
Buy
Level
217.1M
20-day SMA
Buy
Level
$9.70
Relative Strength Index (RSI14)
Buy
Level
50.93
ADX Line
Sell
Level
11.73
Williams %R
Neutral
Level
-55.4217
50-day SMA
Buy
Level
$9.71
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
218.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.6862)
Buy
CA Score
(Annual)
Level (-0.1674)
Buy
Beneish M-Score
(Annual)
Level (-2.6342)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-1.0123)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Stock Forecast FAQ
In the current month, HLN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HLN average analyst price target in the past 3 months is --.
-
Where Will Haleon PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Haleon PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Haleon PLC?
Analysts are divided on their view about Haleon PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Haleon PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Haleon PLC's Price Target?
The price target for Haleon PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HLN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Haleon PLC is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HLN?
You can purchase shares of Haleon PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Haleon PLC shares.
-
What Is The Haleon PLC Share Price Today?
Haleon PLC was last trading at $9.72 per share. This represents the most recent stock quote for Haleon PLC. Yesterday, Haleon PLC closed at $9.72 per share.
-
How To Buy Haleon PLC Stock Online?
In order to purchase Haleon PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.46% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.62% over the past day.
